Introduction
============

Pulmonary tuberculosis (PTB) remains a major cause of death worldwide, accounting for 16.6% of newly diagnosed patients with PTB (an estimated 9.0 million) ([@ref-29]: Global Tuberculosis Report 2014) Antituberculous therapy using the combination of isoniazid (INH), rifampicin (RFP), ethambutol (EB), and pyrazinamide (PZA) has been established as an effective 6-month standard therapy, leading to a decrease in the global incidence of PTB ([@ref-28]: Guidelines for treatment of tuberculosis). However, predictive factors of response to therapy have not been fully elucidated.

Among the standard therapy drugs, PZA has the potential to improve early bactericidal activity of other anti-tuberculosis combination drugs, such as INH-RFP or INH-streptomycin ([@ref-12]). Hence, PZA has been considered a key drug, although the mechanism underlying this additive effect is unclear ([@ref-2]; [@ref-7]; [@ref-13]). In contrast, as PZA could raise concerns about liver dysfunction, especially when administered to elderly patients, the regimen without PZA would be initiated in clinical settings for safety reasons ([@ref-21]). However, patients treated without PZA receive a longer treatment period, which could raise other complications and poor adherence. Thus, the clarification of characteristics of patients who would be recommended for the PZA-including regimen would be important.

Based on the evidence showing that PZA had high bactericidal activity under acidic conditions ([@ref-19]; [@ref-31]), we hypothesized that monitoring airway pH could predict the response to therapy including PZA. The measurement of airway pH using exhaled breath condensate (EBC) has been reported to be useful for evaluating disease severity in patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) ([@ref-1]; [@ref-15]; [@ref-17]; [@ref-24]). Since collecting EBC in patients with PTB would raise safety concerns, we used fresh sputum samples. Our preliminary experiments demonstrated reliable and reproducible pH values in small amounts of sputum samples measured by a high-sensitive pH monitoring system.

This study examined the associations between sputum pH and length to sputum smear and/or culture conversion for the purpose of establishing markers predicting favorable outcomes in patients receiving standard 6-month antituberculous therapy.

Materials & Methods
===================

Subjects
--------

Patients enrolled in this study were newly diagnosed with sputum-microscopy-positive pulmonary tuberculosis and admitted to Yokohama City University Hospital between October 2011 and March 2014 for isolation and treatment. The prevalence of PTB patients in this area was 18 per 100,000 in 2011, which was the same as that in Japan ([@ref-30]: Tuberculosis country profiles). This study was approved by the Institutional Review Board (approval number: B110901018), and all patients provided written informed consent before study enrollment. Enrolled patients were initially treated with INH, RFP, PZA, and EB unless there was pre-existing liver disease or renal impairment. When a patient fulfilled the discharge criteria of at least 3 consecutive determinations of sputum-microscopy conversion (or alternatively at least 3 consecutive determinations of sputum culture conversion for patients showing continued expectoration of dead organisms), patients were referred to their local clinic to complete a standard course of therapy. The exclusion criteria of this study were as follows: subjects with malignancy, subjects who were pregnant, subjects who initiating treatment without PZA, and subjects who could not complete treatment due to intolerable side-effects.

Sample collection
-----------------

Sputum samples were serially obtained before and after initiating antituberculous therapy. Briefly, fresh sputum specimens were collected weekly, just after the patients woke-up, and kept under room temperature (around 22--24 °C) for further analysis. Samples containing bloody sputum were excluded from the data analysis due to possible unreliable pH measurements.

Laboratory measurements
-----------------------

The sputum pH was electrically measured within 3 h of collection using a high-sensitive pH meter with the accuracy to the thousandth (0.001) (model F-71, Horiba, Japan). Medical records of each patient were reviewed. Sputum smears were confirmed by a standard fluorochrome procedure and bacterial load was graded based on the Japanese guidelines using the quantification scale (±, ≥1 acid-fast bacilli (AFB)/300 fields; 1 +, ≥1 AFB/100 fields; 2 +, ≥1 AFB/10 fields; 3 +, ≥10 AFB/fields) ([@ref-9]). Sputum for measurement of time to positivity of tuberculosis was assessed in a liquid culture medium (Middleback7H9). Culture before initiating treatment was tested for susceptibility to antituberculous drugs, and the minimum inhibitory concentrations of INH, RFP, EB and PZA as first-line drugs were examined. Chest radiographs were evaluated for the extent of lung parenchymal involvement and the presence of cavities. For monitoring toxicity, serum samples were serially collected, and other adverse effects, such as peripheral neuropathy and retro-bulbar optic neuropathy, were also evaluated.

Data management and statistical analysis
----------------------------------------

We first evaluated possible independent factors affecting initial sputum pH, including age, sex, smoking history, sputum appearance, sputum bacterial load, use of an acid-suppressant, cavitation, and disease extent. These factors were analyzed by univariate and multivariate logistic regression analysis as dichotomous independent variables, using the following contrasts: age ≥61 vs. \<61 (median); smoking history of current/ex-smoker vs. never smoker; sputum appearance of mucous vs. purulent; sputum bacterial load of ≥2+ vs. \<2+; disease extent of ≥ one whole lung vs. \<one lung; sputum pH ≥7.00 vs. \<7.00 (median) ([@ref-20]). Next, we assessed outcome as defined by the time to smear and culture conversion in patients who completed a 2-month intensive phase of INH, RFP, PZA, and EB (HRZE) followed by a 4-month continuation phase of INH and RFP (HR). As reported previously, sputum bacterial load, extensive lung involvement, and presence of cavities have been demonstrated useful for predicting treatment outcome; therefore, we included these factors in addition to age and sputum pH ([@ref-5]; [@ref-8]; [@ref-10]). Significant differences in sputum pH during storage or treatment were calculated using the paired *t*-test. Univariate analyses using chi-square test or Fisher's exact test were used to compare across potential factors affecting sputum pH. Multivariate logistic regression analysis (forward) was performed to identify significant independent predictors. Independent variables were included in the model when the *p*-value was \<0.20 in each variable because potential confounders should be eliminated only if *p* \> 0.20 in order to prevent residual confounding ([@ref-10]; [@ref-16]). The independence of factors affecting treatment outcome was evaluated by the Cox proportional hazards model. The time to sputum smear and culture conversion was assessed by the log-rank test. A two-tailed *p*-value of \<0.05 was considered statistically significant. Continuous data were expressed as mean ± standard deviation (SD). Statistical analyzes were performed using MedCalc version 15 (Mariakerke, Belgium).

Results
=======

Characteristics
---------------

Forty-seven patients were recruited and enrolled in this study. Of these, 1 patient with liver cancer and 1 pregnant patient were excluded. Furthermore, 2 patients who initiated treatment with HRE due to liver cirrhosis and 4 patients who discontinued treatment with HRZE (INH (5 mg/kg) + RFP (10 mg/kg) + (B \[15 mg/kg) + PZA (25 mg/kg)) during the first 2-month intensive phase due to liver dysfunction (\>5× normal value in an asymptomatic patient and 3× in a symptomatic patient) were excluded. The clinical characteristics of the remaining patients (*n* = 39) are summarized in [Table 1](#table-1){ref-type="table"}. There were 25 male and 14 female patients, and their ages ranged from 16 to 87 years (median, 61 years). Smoking history and acid-suppressant therapy were considered potential factors affecting sputum pH, and thus were further analyzed. There were 17 current smokers and 14 ex-smokers (mean, 40 pack-years), therefore, our cohort might include COPD, although there was only one definitive COPD patient at the time of admission. Chest X-ray showed that 14 patients (35.9%) had extensive pulmonary lesions over one whole lung, and 24 patients (61.5%) had cavities. We confirmed that no patient had a history of bronchial asthma or was co-infected with HIV. Cultures from all patients showed favorable susceptibility to INH, RFP, EB, and PZA.
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###### Baseline characteristics of patients with pulmonary tuberculosis.

![](peerj-03-1448-g005)

  Characteristics                                                      *N* = 39
  -------------------------------------------------------------------- -------------------
  Age, median year (range)                                             61 (16--87)
  Gender---Male, No. (%)                                               25 (64.1)
  Smoking history (current/ex-smoker/never)                            17/14/8
  Use of acid-suppressant, No. (%)[^a^](#table-1fn1){ref-type="fn"}    14 (35.9)
  Immunocompromised, No. (%) [^b^](#table-1fn2){ref-type="fn"}         13 (33.3)
  Extensive lung lesion, No. (%)[^c^](#table-1fn3){ref-type="fn"}      14 (35.9)
  Presence of cavities, No. (%)                                        24 (61.5)
  Sputum appearance, M1/M2/P1/P2/P3[^d^](#table-1fn4){ref-type="fn"}   5/5/10/11/8
  Sputum bacterial load, scanty /1 + /2 + /3 +                         2/15/8/14
  Sputum pH, median (range)                                            7.00 (5.50--8.37)

**Notes.**

Acid-suppressant including histamine-2 receptor antagonist and proton pump inhibitor.

Immunocompromised; Patients having diabetes mellitus and/or corticosteroid user.

Extensive lung lesion; Radiological extent of parenchymal disease over one whole lung.

Sputum appearance classified by Miller and Jones' classification.

Analysis of factors affecting sputum pH
---------------------------------------

The sputum pH was uniformly-distributed between 5.50 and 8.37, with a median value of 7.00, from 39 included patients ([Fig. 1](#fig-1){ref-type="fig"} and [Table 1](#table-1){ref-type="table"}). First, we examined whether the sputum pH could be reproducible under the conditions of (1) different time points after sample collection and (2) different temperatures of sample preservation. Our preliminary studies showed that the value of sputum pH did not differ up to 6 h after collection, regardless of storage temperature ([Fig. 2](#fig-2){ref-type="fig"}). Of particular importance, there was no significant change in sputum pH before and 2 months after initiating treatment with HRZE ([Fig. 3](#fig-3){ref-type="fig"}, *p* = 0.68, *n* = 19). The potential clinical characteristics associated with sputum pH were analyzed and summarized in [Table 2](#table-2){ref-type="table"}. In univariate analysis, age ≥61 years was a statistically important factor predicting low pH value (*p* \< 0.01 vs. aged \<61 years). Of note, there was an inverse association between age and sputum pH value (*r* = − 0.56, *p* \< 0.01, *n* = 39). Unexpectedly, smoking history and extensive lung lesions did not affect the sputum pH values. The use of an acid-suppressant (*p* = 0.048), being immunocompromised (*p* = 0.096), the presence of cavities (*p* = 0.105), and sputum bacterial load (*p* = 0.111) were potential predictors of sputum pH ([Table 2](#table-2){ref-type="table"}). Multivariate analysis identified that only age ≥61 years was an independent predictor of low sputum pH (*p* = 0.005; odds ratio (OR) 24.535; 95% CI \[2.685--224.213\].

![Distribution of initial sputum pH before treatment in pulmonary tuberculosis patients.\
The pH of freshly collected sputum samples was measured according to the Methods section. In the 39 patients included, the median value of initial sputum pH was 7.00.](peerj-03-1448-g001){#fig-1}

![Changes in sputum pH after collecting samples in pulmonary tuberculosis patients.\
Serial analysis of pH in freshly collected sputum samples (*n* = 14) was made up to 6 h under deferent temperature conditions: (A) 4 °C or (B) room temperature. Statistical analysis was performed by using paired-*t* test.](peerj-03-1448-g002){#fig-2}

![Changes in sputum pH before and after treatment in pulmonary tuberculosis patients.\
Paired sputum samples from patients before and 2 months after initiating antituberculous therapy are shown. Statistical analysis was paired *t*-test.](peerj-03-1448-g003){#fig-3}
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###### Univariate and multivariate analyses of odds ratio for an initial low sputum pH (\<7.00).
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                                                               Univariate analysis   Multivariate analysis                                     
  ------------------------------------------------------------ --------------------- ----------------------- ------- -------- ---------------- -------
  Age ≥61 yr                                                   8.750                 2.100--36.251           0.004   24.535   2.685--224.213   0.005
  Male sex                                                     2.291                 0.613--8.498            0.320                             
  Smoking history (current/ex-smoker vs. never)                0.938                 0.214--4.108            1.000                             
  Use of acid-suppressant[^a^](#table-2fn2){ref-type="fn"}     4.444                 1.115--17.497           0.048                             
  Immunocompromised[^b^](#table-2fn3){ref-type="fn"}           3.600                 0.905--14.132           0.096                             
  Extensive lung lesion[^c^](#table-2fn4){ref-type="fn"}       1.697                 0.466--6.165            0.514                             
  Presence of cavities                                         0.300                 0.080--1.130            0.105                             
  Sputum appearance[^d^](#table-2fn5){ref-type="fn"}(M vs P)   0.542                 0.134--2.219            0.480   0.104    0.010--1.128     0.063
  Sputum bacterial load (\<2+ vs ≥2+)                          3.208                 0.877--11.719           0.111                             

**Notes.**

CIconfidence intervalORodds ratio

Acid-suppressant including histamine-2 receptor antagonist and proton pump inhibitor.

Immunocompromised; Patients having diabetes mellitus and/or corticosteroid user.

Extensive lung lesion; Radiological extent of parenchymal disease over one whole lung.

Sputum appearance classified by Miller and Jones' classification.

Fisher's exact test.

^¶^ Logistic regression.

Analysis of sputum pH and outcome
---------------------------------

We further analyzed the association between initial sputum pH and clinically important outcome, including the time to, (1) smear conversion and (2) culture conversion of sputum, as useful indicators of response to treatment with HRZE. Among the 39 patients included, 5 patients showing persistent smear-positive results fulfilled the discharge criteria. Therefore, the remaining 34 patients were examined as evaluable smear-conversion subjects. There was a moderate positive relationship between initial sputum pH and time to smear conversion (*r* = 0.342, *p* = 0.048, *n* = 34). Similarly, initial sputum pH was modestly correlated with time to culture conversion (*r* = 0.304, *p* = 0.060, *n* = 39). Further, when patients were divided into initial sputum pH \<7.00 vs. ≥7.00 (median for whole group) groups, the low pH group showed significantly shorter hospital stay as determined by time to smear conversion (29.6 ± 31.0 vs. 61.5 ± 32.5 days \[mean ± SD\], *p* = 0.028, log-rank test) or alternatively, time to culture conversion (30.5 ± 17.9 vs. 51.4 ± 19.4 days \[mean ± SD\], *p* = 0.007, log-rank test) as shown in [Fig. 4](#fig-4){ref-type="fig"}. Since age was shown to be significantly correlated with sputum pH ([Table 2](#table-2){ref-type="table"}), we evaluated the effect of age on outcome analysis. Also, known factors such as sputum bacterial load, extent of lung lesion, and cavity formation have been thought of as biomarkers to identify PTB patients at risk of longer hospital stays and relapse ([@ref-5]; [@ref-8]; [@ref-10]), and thus be included in multivariate Cox regression analysis. Interestingly, although age ≥61 years is also a factor affecting initial low sputum pH, the lack of significance between age and response to therapy is identified ([Tables 2](#table-2){ref-type="table"} and [3](#table-3){ref-type="table"}). This is convincing because elder PTB patients exhibit higher mortality ([@ref-4]). Possible reasons of this dissociation are thought to be treatment interruption and/or discontinuation due to multiple organ dysfunctions caused by initiating therapy in elder patients. However, 14 (30%) of the 47 patients enrolled in the current study were aged 75 years or older, and the majority (*n* = 12, 86%) of these patients could continue HRZE, and could be discharged from hospital. Thus, older age may not always associate with higher mortality in PTB. Importantly, other potential factors such as sputum bacterial load, extensive lung involvement, and cavity formation did not affect the outcome analysis using a multivariate Cox regression model in our cohort ([Table 3](#table-3){ref-type="table"}). Accordingly, sputum pH was found to be the most powerful independent predictor of the time to both sputum smear and culture conversion in patients receiving the standard 2-month HRZE followed by a 4-month HR therapy ([Table 3](#table-3){ref-type="table"}, *p* = 0.034 and 0.019, respectively).

![The time to sputum smear and culture conversion in pulmonary tuberculosis patients.\
Thirty-nine included patients were divided into groups according to median initial sputum pH. Kaplan--Meier Curves of time to (A) sputum smear conversion and (B) sputum culture conversion were made in low (pH \< 7.00) and high (pH ≥ 7.00) sputum pH groups, and analyzed using the log-rank test. Ticks indicate censored data.](peerj-03-1448-g004){#fig-4}
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###### Cox regression analysis for baseline predictors of sputum smear and culture conversion in patients.
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                                                            Predictor variable   Hazard ratio   95% CI         *P*
  --------------------------------------------------------- -------------------- -------------- -------------- -------
  Sputum smear conversion (days)                            Age ≥61 yr           1.910          0.724--5.036   0.193
  Sputum bacterial load[^a^](#table-3fn2){ref-type="fn"}    1.465                0.644--3.334   0.366          
  Extensive lung lesion [^b^](#table-3fn3){ref-type="fn"}   0.543                0.221--1.334   0.185          
  Presence of cavities [^c^](#table-3fn4){ref-type="fn"}    1.825                0.845--3.941   0.128          
  Sputum pH ≥7.0                                            3.094                1.093--8.760   0.034          
  Sputum culture conversion (days)                          Age ≥61 yr           1.556          0.724--3.347   0.260
  Sputum bacterial load [^a^](#table-3fn2){ref-type="fn"}   1.390                0.650--2.974   0.398          
  Extensive lung lesion[^b^](#table-3fn3){ref-type="fn"}    0.723                0.322--1.623   0.434          
  Presence of cavities [^c^](#table-3fn4){ref-type="fn"}    2.044                0.894--4.673   0.092          
  Sputum pH ≥ 7.0                                           2.717                1.183--6.240   0.019          

**Notes.**

CIconfidence interval

Dummy variables for sputum bacterial load: 0 for bacterial load \<2+, 1 for bacterial load ≥2+.

Dummy variables for extensive lung lesion: 0 for lung lesion \< one whole lung, 1 for lung lesion ≥ one whole lung.

Dummy variables for presence of cavities: 0 for no cavity, 1 for presence of ≥ one cavity.

Discussion
==========

The sputum sample provides important information in both infectious and non-infectious pulmonary diseases ([@ref-3]; [@ref-14]; [@ref-26]). Previous reports have documented that the analysis of pH in sputum or EBC could monitor the inflammatory status in various lung diseases, and might reflect the success of subsequent therapy ([@ref-1]; [@ref-11]; [@ref-15]; [@ref-17]). Although low pH in sputum or EBC indicates airway acidity, which disadvantageously affects host defense and immune activation ([@ref-22]; [@ref-23]), several antibiotics, such as PZA, have more bactericidal activity in acidic conditions ([@ref-19]; [@ref-31]). Based on these facts, we hypothesized that measuring pH in sputum or EBC would be useful for predicting response to therapy in PTB, because they require long-term treatment with careful management of several side effects.

One serious concern was accidental exposure to medical staff, especially when collecting the EBC samples. In contrast, sputum samples can be easily collected and mandatory assessment of isolation in patients with smear-positive active PTB. In addition, measuring pH is quite easy using an electrode or even by dipstick test. Since there have been few reports on the analysis of sputum pH, we needed to establish an appropriate procedure of measurement and analysis.

Our preliminary experiment revealed that the pH value of sputum was uniformly distributed, and was reproducible up to 6 h under either cold conditions or room temperature ([Figs. 1](#fig-1){ref-type="fig"} and [2](#fig-2){ref-type="fig"}). Unfortunately, we could not establish the control value because collecting sputum samples from healthy subjects was quite difficult. However, EBC or induced sputum from healthy subjects revealed the normal pH value around 7.5--7.7. ([@ref-14]; [@ref-15]; [@ref-27]). Our PTB patients showed a relatively acidic airway environment (pH = 7.02 ± 0.89). Low pH values of EBC and induced sputum were also addressed in patients with asthma, COPD, and acute lung injury, where such values were associated with resistance to therapy ([@ref-1]; [@ref-6]; [@ref-17]). However, current findings show, for the first time, that an initial low pH value of sputum in PTB patients was the most powerful indicator predicting a favorable response to standard combination therapy ([Table 3](#table-3){ref-type="table"} and [Fig. 4](#fig-4){ref-type="fig"}).

Next, we considered the reason for good prognosis in PTB patients with low pH sputum. A potential benefit of low pH in the lung lesion is that PZA has much more bactericidal activity in acidic conditions ([@ref-19]). When administered in an acidic lesion, PZA is easily degraded into an activated form of pyrazinoic acid and accumulated in bacterial cytoplasm, which facilitates bactericidal activity ([@ref-31]). Second, bacteria, even tuberculosis, is thought to be intolerable to acidic conditions ([@ref-18]). Acidic conditions and the administration of PZA could act synergistically to kill tuberculosis, and thus lead to favorable shorter hospital stays in PTB patients presenting with low sputum pH. Our findings could support the establishment of a future new shorter regimen including PZA and the selection of eligible patients for a PZA-including regimen.

The current study has several limitations. First, the number of patients is limited, and the patients were recruited from a single hospital, limiting the generalizability of treatment regimen and results. Actually, we have tried to apply intensified treatment with HRZE even in patients older than 80 years, and 91.4% (*n* = 43) of eligible patients initiated therapy with HRZE, and 90.7% (*n* = 39) of them successfully completed 2 months HRZE without serious adverse events. The remaining patients (17.0%, *n* = 8) could not initiate therapy including PZA, or discontinued PZA due to liver dysfunction. We could not compare the outcome with or without PZA, in this relatively small group. Second, our cohort consists of single ethnic Japanese patients with favorable susceptibility to INH, RFP, EB, and PZA. That is, relatively low prevalence of drug resistance PTB (approximately 3.2% to any drug including INH, RFP, and EB among newly diagnosed patients in Japan) should be considered ([@ref-25]). Thus, our findings may not be applicable to other unique populations. Third, we could follow and collect samples until patients fulfilled the discharge criteria. Therefore, we could not determine if their sputum pH reversed to normal, around 7.7--8.0, after completing treatment. Since this should be clarified, we are planning to monitor long-term sputum pH with a large number of PTB patients as a validation cohort from another center.

Conclusions
===========

Airway acidity is easily monitored using sputum samples, which might enable us to predict response to standard intensified therapy of HRZE in patients with PTB.
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###### Raw dataset of 39 included patients

###### 

Click here for additional data file.
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###### Raw dataset of 39 included patients for logistic analysis

###### 

Click here for additional data file.

The authors thank the nursing and laboratory staff of Yokohama City University Hospital.

Additional Information and Declarations
=======================================

The authors declare there are no competing interests.

[Makoto Masuda](#author-1){ref-type="contrib"} conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Takashi Sato](#author-2){ref-type="contrib"} conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

[Kentaro Sakamaki](#author-3){ref-type="contrib"} analyzed the data, reviewed drafts of the paper.

[Makoto Kudo](#author-4){ref-type="contrib"} and [Takeshi Kaneko](#author-5){ref-type="contrib"} conceived and designed the experiments, reviewed drafts of the paper.

[Yoshiaki Ishigatsubo](#author-6){ref-type="contrib"} conceived and designed the experiments, contributed reagents/materials/analysis tools, reviewed drafts of the paper.

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Yokohama City University Institutional Review Board

Approval number: B110901018.

The following information was supplied regarding data availability:

The summarized dataset sheets are provided as [Datas S1](#supp-1){ref-type="supplementary-material"} and [S2](#supp-2){ref-type="supplementary-material"}.
